Neal Rosen: Featured News

Share
Print
Share
Print
In the Clinic
Piro Lito, Bob Li, and Neal Rosen in the lab
Promising Results from the First-Ever Trial of a Drug that Blocks Cancer Gene KRAS
Summary In a study of people with lung cancer whose tumors contained the mutation targeted by sotorasib, 52 of 59 patients experienced disease con...
In the Lab
Scott Lowe and Neal Rosen
Knocking Out KRAS-Mutant Cancers with a One-Two Punch
Summary A new approach aims to combine two existing targeted therapy drugs to attack lung cancer and pancreatic cancer with mutations in the hard-...
In the Lab
Colored x-ray of lung cancer
New Lung Cancer Therapy May Target Previously Untreatable Tumors
Summary Although some lung cancer patients have benefited from developments in precision therapy, those with mutations in a gene called KRAS have ...
In the Clinic
Memorial Sloan Kettering medical oncologist Andrea Cercek
FDA Approval Gives Hope to Some People with Advanced Colorectal Cancer
Summary People with colorectal cancer whose tumors carry a mutation called BRAF V600E have not done well under standard therapies after earlier tr...
In the Lab
MSK investigators Joan Massagué and Anna Obenauf
Outsmarting Cancer’s Survival Skills
Summary Most cancers treated with targeted therapy ultimately become resistant to treatment, stop shrinking, and eventually progress. New research...
Profile
Pictured: David Solit
At Work: Physician-Scientist David Solit
Summary David Solit, Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, discusses how working with cancer patients dri...
Honors
Five Memorial Sloan Kettering researchers have been named to Stand Up To Cancer's new Melanoma "Dream Team."
Memorial Sloan Kettering Researchers Appointed to Stand Up To Cancer Melanoma “Dream Team”
Summary Five Memorial Sloan Kettering scientists have been appointed to a new research team dedicated to identifying targets for therapies t...